PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2008Journal of Clinical Oncology2,930 citationsOpen Access

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

CLCornelia LiedtkeCMChafika MazouniKHKenneth R. Hess

Key Points

  • To evaluate the impact of pathologic response following neoadjuvant chemotherapy on long-term survival outcomes in patients with triple-negative breast cancer compared to non-triple-negative breast cancer.
  • Assessed response to neoadjuvant chemotherapy in patients with triple-negative breast cancer (TNBC) versus non-TNBC.
  • Categorized outcomes by the presence of pathologic complete response (pCR) versus residual disease (RD) and monitored survival.
  • Patients with TNBC achieved higher pCR rates than those with non-TNBC, with pCR conferring excellent long-term survival.
  • Patients with residual disease following neoadjuvant chemotherapy experienced significantly worse survival if they had TNBC compared with non-TNBC, predominantly within the first 3 years.

Abstract

Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival. However, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with non-TNBC, particularly in the first 3 years.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liedtke et al. (2008) studied this question.

synapsesocial.com/papers/69d6ceb9733a2b54c8aa84a1https://doi.org/10.1200/jco.2007.14.4147
Ask AI
Helpful
Bookmark
Share
View Full Paper